| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| LB PHARMACEUTICALS INC | Chief Executive Officer, Director | Employee Stock Option (Right to Buy) | 972K | Sep 10, 2025 | Direct | ||
| Lyell Immunopharma, Inc. | Chief General Counsel | Option (right to buy) | 300K | Mar 16, 2022 | Direct | ||
| Terns Pharmaceuticals, Inc. | Director | Stock Option (Right to Buy) | 45K | Jun 11, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| LBRX | LB PHARMACEUTICALS INC | Sep 10, 2025 | 5 | $0 | 4 | Sep 12, 2025 | Chief Executive Officer, Director |
| LBRX | LB PHARMACEUTICALS INC | Sep 10, 2025 | 0 | $0 | 3 | Sep 10, 2025 | Chief Executive Officer, Director |
| TERN | Terns Pharmaceuticals, Inc. | Jun 11, 2025 | 1 | $0 | 4 | Jun 12, 2025 | Director |
| TERN | Terns Pharmaceuticals, Inc. | Nov 18, 2024 | 1 | $0 | 4 | Nov 19, 2024 | Director |
| TERN | Terns Pharmaceuticals, Inc. | Nov 18, 2024 | 0 | $0 | 3 | Nov 19, 2024 | Director |
| LYEL | Lyell Immunopharma, Inc. | Mar 16, 2022 | 1 | $0 | 4 | Mar 18, 2022 | Chief General Counsel |
| LYEL | Lyell Immunopharma, Inc. | Jun 16, 2021 | 0 | $0 | 3 | Jun 16, 2021 | Chief General Counsel |